with a decision by April 2025. Pre-filled syringes of high-dose aflibercept are expected to launch by mid-2025, pending FDA approval. Successful QUASAR trial results support a supplemental biologics ...

paternity and child care leave applications. Despite submitting their representations more than three months ago, they... The Tribune, now published from Chandigarh, started publication on ...

The algorithm’s computational efficiency and robustness make it suitable for real-time applications, as validated using real recordings from the SPeech Enhancement for Augmented Reality (SPEAR) ...